Bristol Myers wins FDA approval for first drug to treat inherited heart condition

Bristol Myers paid $13 billion to acquire the drug’s maker, MyoKardia, and expects it to become a blockbuster. But a tricky dosing regimen, as well as safety concerns, could challenge the pharmaceutical giant’s lofty forecast.